Research

Helping develop the next generation of advanced treatments through research is part of our mission at Kadima Neuropsychiatry

Our Research

Kadima Neuropsychiatry conducts clinical trials of cutting-edge, experimental novel treatments for various mental health conditions, including depression and treatment-resistant depression, generalized anxiety disorder, and PTSD. The experimental treatments that are currently, or soon to be, tested at KADIMA, for a variety of psychiatric conditions, include psilocybin, LSD, DMT, alternate form of ketamine, other medications with novel mechanisms of action, innovative medical devices, digital mental health apps, and virtual reality. If you want to learn more about the studies we’re doing, please ask! 

Research

Active Research

Beckeley

Study assessing LSD for the Treatment of Anxiety Symptoms

Investigational Treatment:  This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM-120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD). Learn more about the investigational treatment.

Read more about this study…

Effects of a Virtual Reality PsyAssist Calm Experience Program on Pre-treatment Anxiety Prior to Ketamine Dosing

Sponsor: TRIPP PsyAssist

Investigational Treatment: TRIPP PsyAssist is a virtual reality meditation program that aims to reduce pre-treatment anxiety in ketamine patients with anxiety symptoms.  – Learn more about the investigational treatment

 

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) (RELIANCE-II)

Investigational Treatment:  REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Learn more about the investigational treatment.

Read more about this study…

Cognitive Behavioral Therapy (CBT) in adjunct with Deep Transcranial Magnetic Stimulation (dTMS) for Major Depressive Disorder (MDD)

Sponsor: Brainsway

Investigational Treatment:  CBT-based, mobile-delivered, intervention platform. Learn more about the investigational treatment.

Read more about this study…

Study assessing an novel NMDA receptor modulator for Major Depressive Disorder

Investigational Treatment:  REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Learn more about the investigational treatment.

Read more about this study…

Study evaluating a Brain Neuromodulation system for the Treatment of Major Depressive Disorder (MDD).

Investigational Treatment:  Relivion®DP is a non-invasive and multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders  – Learn more about the investigational treatment

Read more about the study…

Upcoming Research

Study of Psilocybin for Treatment Resistant Depression

Study of 5MeO-DMT for Treatment Resistant Depression

Learn About Kadima's Advanced Treatments for Mental Health

compassion
atai
introspect
brainsway

Recently Completed Trials

1. Compass Pathways, COMP001
The safety and efficacy of psilocybin in participants with Treatment Resistant Depression. Read More

2. Compass Pathways, COMP003
The safety and efficacy Of psilocybin as an adjunctive therapy in participants with Treatment Resistant Depression.  Read More

3. Perception Neuroscience, Inc, PCN-101
The safety and efficacy of PCN-101 (R-Ketamine) in participants with Treatment Resistant Depression. Read More

Get in Contact

Address: 3252 Holiday Court, Suite 112 La Jolla, CA 92037

Email: info@kadimanp.com

(858)412-4130

Scroll to Top